Companies Dominating the Scopolamine Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Baxter International Inc.
- Myungmoon Pharm Co. Ltd
- Alchem International Pvt. Ltd.
- Caleb Pharmaceuticals, Inc.
- GlaxoSmithKline plc
- Aktivax, Inc.
- Southwest Research Institute
- Perrigo Company plc
- Novartis International AG
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of scopolamine is assessed at USD 556.1 billion.
The scopolamine market size was valued at USD 511.78 billion in 2024 and is expected to reach USD 1001.5 billion by 2037, expanding at around 5.3% CAGR during the forecast period i.e., between 2025-2037. Increasing number of surgical procedures, the number of people suffering from digestive disorders, and psychological disorders will boost the market growth.
Asia Pacific industry is estimated to dominate majority revenue share of 32% by 2037, attributed to increasing number of people suffering from ophthalmic disorders and the increasing number of surgeries in the elderly population.
The major players in the market are Pfizer Inc., Baxter International Inc., Myungmoon Pharm Co. Ltd, Alchem International Pvt. Ltd., Caleb Pharmaceuticals, Inc., GlaxoSmithKline plc, Aktivax, Inc., Southwest Research Institute, Perrigo Company plc, Novartis International AG
